Kestra Medical Technologies (KMTS) director adds 10,000 shares in open-market buy

Rhea-AI Filing Summary

Kestra Medical Technologies director Raymond W. Cohen bought 10,000 Common Shares of KMTS in an open-market purchase at a weighted average price of $19.98 per share. After this transaction, he directly owns 50,903 Common Shares. The footnote explains the trade prices ranged from $19.82 to $20.02 per share.

Insider Trade Summary

Net Buyer: 10,000 shares ($199,800)

Net Buy 1 txn

Insider COHEN RAYMOND W

Role Director

Bought 10,000 shs ($200K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	10,000	$19.98	$200K

Holdings After Transaction: Common Shares — 50,903 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 10,000 shares Weighted average price: $19.98 per share Price range: $19.82–$20.02 per share +1 more

4 metrics

Shares purchased 10,000 shares Open-market purchase of Common Shares

Weighted average price $19.98 per share Price paid for 10,000 Common Shares

Price range $19.82–$20.02 per share Range of individual trade prices in the transaction

Shares owned after transaction 50,903 shares Director’s direct ownership following the purchase

Key Terms

open-market purchase, Common Shares, weighted average price

3 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Shares financial

""security_title": "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

weighted average price financial

"The price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COHEN RAYMOND W

(Last) (First) (Middle)

C/O KESTRA MEDICAL TECHNOLOGIES LTD.

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/26/2026		P		10,000	A	$19.98(1)	50,903	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $19.82 to $20.02. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

	/s/ Traci S. Umberger as attorney-in-fact for Raymond W. Cohen	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Kestra Medical Technologies (KMTS) report?

Kestra Medical Technologies reported that director Raymond W. Cohen completed an open-market purchase of 10,000 Common Shares. The transaction was recorded as a Form 4 filing and reflects a direct increase in his personal share ownership in KMTS.

At what price did the KMTS director buy shares in this Form 4 filing?

The director bought the 10,000 Kestra Medical Technologies shares at a weighted average price of $19.98. A footnote states individual trade prices ranged between $19.82 and $20.02, with detailed price breakdowns available upon request from the reporting person.

How many Kestra Medical Technologies (KMTS) shares does the insider own after this trade?

After the 10,000-share open-market purchase, director Raymond W. Cohen directly owns 50,903 Common Shares of Kestra Medical Technologies. This total reflects his updated direct ownership as reported in the Form 4 following the reported transaction date.

Was the KMTS insider transaction in this Form 4 a purchase or a sale?

The Form 4 for Kestra Medical Technologies shows a purchase transaction. It is coded as an open-market purchase (transaction code P), indicating the insider bought 10,000 Common Shares rather than selling or disposing of existing holdings.

What does the weighted average price range mean in the KMTS Form 4 footnote?

The footnote explains that the $19.98 price is a weighted average across multiple trades. Individual trades were executed at prices between $19.82 and $20.02, and the reporting person offers to provide the exact share counts at each price upon request.